# Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

> **NCT05854849** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 244 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT05854849
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05854849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05854849, "Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05854849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*